CAeditome Logo

Home

Download

Statistics

Landscape

Help

Contact
Center for Computational Systems Medicine
Soverview

1. Gene summary of enriched editing regions

Soverview

2. Tumor-specific enriched editing regions

Comparison of enriched editing regions between tumor and normal.

Correlation of enriched editing regions with tumor stages.

Associations of enriched editing regions with cancer survival.

Soverview

3. Enriched editing regions and immune related genes

Soverview

4. Enriched editing regions and immune related splicing

Soverview

5. Enriched editing regions and immune infiltration

Soverview

6. Enriched editing regions and immune gene sets

Correlation of enriched editing regions with epithelial-mesenchymal transition.

Correlations of enriched editing regions with hypoxic.

Associations of enriched editing regions with hallmark gene sets from MSigDB.

Soverview

7. Enriched editing regions and drugs

Correlations between enriched editing regions and drug sensitivity.

Enriched editing regions targeted by drugs from DrugBank database.

Editing gene: PDP2 (ImmuneEditome ID:57546)

1. Gene summary of enriched editing regions for PDP2

check button Gene summary
Gene informationGene symbol

PDP2

Gene ID

57546

GeneSynonymsPDPC 2|PPM2B|PPM2C2
GeneCytomap

16q22.1

GeneTypeprotein-coding
GeneDescription[Pyruvate dehydrogenase [acetyl-transferring]]-phosphatase 2, mitochondrial|protein phosphatase 2C, magnesium-dependent, catalytic subunit 2|protein phosphatase, Mg2+/Mn2+ dependent 2B|pyruvate dehydrogenase phosphatase isoenzyme 2|pyruvate dehyrogenase phosphatase catalytic subunit 2
GeneModificationdate20230518
UniprotIDQ9P2J9;H3BRB7;H3BSA5;H3BTU5;H3BQX2;H3BV50
PubMed ID

check buttonUCSC image.
all structure

check buttonLocations of each EERs.
EERENSTENSGGeneNameRegionRepeatdsRNA structure
chr16:66887640-66890279:+ENST00000561475.2ENSG00000172840.5PDP2ncRNA_exonicAluSz,AluSq2,(TCCT)n,AluJr,AluJb,AluSpchr16:66887640-66890279:+.alignment


Top

2. Tumor-specific enriched editing regions for PDP2


all structure

check buttonComparison of enriched editing regions between tumor and normal.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
ID_eventscancerTypePBoxplot
chr16:66887640-66890279:+BRCAEER4.7598e-08image
ENSG00000172840.5,PDP2BRCAEAG4.7598e-08image
chr16:66887640-66890279:+COADEER1.6314e-02image
ENSG00000172840.5,PDP2COADEAG1.6316e-02image
chr16:66887640-66890279:+KICHEER1.2899e-02image
ENSG00000172840.5,PDP2KICHEAG1.2899e-02image
chr16:66887640-66890279:+KIRCEER3.8772e-12image
ENSG00000172840.5,PDP2KIRCEAG3.3470e-12image
chr16:66887640-66890279:+KIRPEER9.0482e-10image
ENSG00000172840.5,PDP2KIRPEAG9.0482e-10image
chr16:66887640-66890279:+THCAEER6.9255e-06image
ENSG00000172840.5,PDP2THCAEAG6.9255e-06image


Top

check buttonCorrelation of enriched editing regions with tumor stages.
* AnovaP<0.05, Pearson P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes, Path: Pathological stage, Cli: Clinical stage.
* Only shows the most significant correlation result of EERs/EAGs with either pathological stage or clinical stage according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeStageTypeAnovaPPRBoxplot
chr16:66887640-66890279:+KICHPathEER4.5516e-022.8298e-020.2722image
ENSG00000172840.5,PDP2KICHPathEAG4.5516e-022.8298e-020.2722image
ENSG00000172840.5,PDP2THCAPathEAG2.9562e-021.0852e-020.1142image
chr16:66887640-66890279:+THCAPathEER2.9562e-021.0852e-020.1142image


Top

check button Associations of enriched editing regions with cancer survival.
* Pkm<0.05 and Pcox<0.05.
* EER: enriched editing region, EAG: EER-associated genes.
ID_eventscancerTypeIDPkmPcox_continuousHR_continuousKMPlot

Top

3. Enriched editing regions and immune related genes for PDP2


all structure

check button Enriched editing regions and immune related genes.
* First, the associations between enriched editing regions and genes were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).
* Second, the gene relationships with immune were tested by three analyses: whether the gene is an immune gene (InnateDB、Immport、Immunome、Immunogenetic Related Information Source (IRIS)), whether the gene is associated with immune infiltration and whether the gene is related to immune gene sets.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of genes with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeGenebetaFDRPearsonPPearsonRCorrelationPlotRBPRBPtargetsImmuneGeneImmuneFractionHallMark
chr16:66887640-66890279:+LGGEERENSG00000011422,PLAUR0.19741.2876e-043.2999e-280.4579imageNEIF4A3;ELAVL1;FUS;HNRNPK;IGF2BP2;RBFOX2;TARDBPPLAURT_cells_CD4_naiveGSVA_HALLMARK_TNFA_SIGNALING_VIA_NFKB
chr16:66887640-66890279:+LGGEERENSG00000108821,COL1A10.15782.8745e-034.9143e-280.4566imageNEIF4A3;ELAVL1;FUS;IGF2BP2;RBFOX2;TARDBP;WTAPCOL1A1Macrophages_M0GSVA_HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION
chr16:66887640-66890279:+LGGEERENSG00000119681,LTBP20.14318.1072e-033.3618e-260.4421imageNEIF4A3;ELAVL1;FUS;HNRNPK;IGF2BP2;RBFOX2;TARDBP;WTAPLTBP2T_cells_CD4_naiveGSVA_HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION
chr16:66887640-66890279:+LGGEERENSG00000107438,PDLIM10.12152.5389e-022.1261e-220.4098imageNEIF4A3;ELAVL1;FUS;HNRNPK;IGF2BP2;RBFOX2;TARDBPNAMacrophages_M0GSVA_HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION
chr16:66887640-66890279:+LGGEERENSG00000139329,LUM0.11693.4953e-024.0644e-250.4333imageNEIF4A3;ELAVL1;FUS;IGF2BP2NAMacrophages_M0GSVA_HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION
chr16:66887640-66890279:+LGGEERENSG00000137962,ARHGAP290.11024.9290e-021.5853e-230.4198imageNEIF4A3;ELAVL1;FUS;HNRNPK;IGF2BP2;RBFOX2;TARDBPNAMacrophages_M1GSVA_HALLMARK_ANGIOGENESIS
chr16:66887640-66890279:+COADEERENSG00000206650,SNORA70G0.14893.5228e-021.7344e-110.4022imageNNNAEosinophilsGSVA_HALLMARK_UV_RESPONSE_UP
chr16:66887640-66890279:+GBMEERENSG00000172840,PDP2-0.49337.4980e-077.6876e-11-0.4923imageNEIF4A3;ELAVL1;FUS;HNRNPK;IGF2BP2;RBFOX2;TARDBPNAMast_cells_restingGSVA_HALLMARK_P53_PATHWAY
chr16:66887640-66890279:+GBMEERENSG00000223722,RP11-467L13.50.41418.4536e-051.1965e-080.4380imageNNNAMacrophages_M1GSVA_HALLMARK_INTERFERON_GAMMA_RESPONSE
chr16:66887640-66890279:+GBMEERENSG00000070770,CSNK2A2-0.41101.0932e-041.7292e-07-0.4049imageNEIF4A3;ELAVL1;FUS;HNRNPK;IGF2BP2;RBFOX2;TARDBP;WTAPNAMacrophages_M0GSVA_HALLMARK_MITOTIC_SPINDLE

More results



Top

4. Enriched editing regions and immune related splicing for PDP2


all structure

check button Enriched editing regions and immune related splicing.
* First, the associations between enriched editing regions and splicing events were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).
* Second, the splicing relationships with immune were tested by three analyses: whether the splicing event locates in an immune gene (InnateDB、Immport, Immunome and Immunogenetic Related Information Source (IRIS)), whether the splicing event is associated with immune infiltration and whether the splicing event is related to immune gene sets.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of splicing events with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeSplicingTypeSplicingGeneSplicingChrSplicingPositionbetaFDRPearsonPPearsonRCorrelationPlotRBPRBPtargetsImmuneGeneImmuneFractionHallMark
ENSG00000172840.5,PDP2
COADEAGMEXENSG00000214078.7chr2035627284:35627413:35630438:35630455:35630740:35630795:35630900:356310340.23813.5413e-024.9035e-150.4610imageNADAR;AIFM1;ALYREF;BCCIP;BUD13;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;DICER1;DKC1;EIF4A3;EIF4G2;ELAVL1;ELAVL3;EWSR1;FAM120A;FBL;FMR1;FTO;FUS;FXR1;FXR2;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHDRBS2;KHDRBS3;KHSRP;LIN28;LIN28A;LIN28B;LSM11;METTL3;MOV10;MSI2;NONO;NOP56;NOP58;NUMA1;PCBP2;PRPF8;PTBP1;QKI;RANGAP1;RBFOX2;RBM27;RBM47;RBM5;RC3H1;RTCB;SAFB2;SLTM;SMNDC1;SND1;SRSF1;SRSF3;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TIAL1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;XRN2;YTHDC1;YTHDF1;YTHDF2;ZC3H7B;ZNF184NADendritic_cells_activatedGSVA_HALLMARK_SPERMATOGENESIS
chr16:66887640-66890279:+
COADEERMEXENSG00000138041.11chr255568193:55568363:55573618:55573777:55579678:55579781:55581566:55581698-0.23922.6824e-021.2157e-12-0.4226imageNNNAEosinophilsGSVA_HALLMARK_P53_PATHWAY
ENSG00000172840.5,PDP2
COADEAGMEXENSG00000151247.8chr498884921:98885061:98887078:98887167:98891236:98891332:98901875:98901982-0.32942.6864e-041.0178e-11-0.4064imageNADAR;AIFM1;BCCIP;BUD13;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;DICER1;DKC1;EIF4A3;EIF4G2;ELAVL1;ELAVL3;EWSR1;FAM120A;FBL;FMR1;FTO;FUS;FXR1;FXR2;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHDRBS2;KHDRBS3;KHSRP;LIN28;LIN28A;LIN28B;LSM11;METTL3;MOV10;MSI2;NONO;NOP56;NOP58;NUMA1;PCBP2;PRPF8;PTBP1;QKI;RANGAP1;RBFOX2;RBM27;RBM47;RBM5;SAFB2;SLTM;SMNDC1;SND1;SRSF1;SRSF3;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TIAL1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;XRN2;YTHDC1;ZC3H7B;ZNF184EIF4EEosinophilsGSVA_HALLMARK_DNA_REPAIR
ENSG00000172840.5,PDP2
COADEAGMEXENSG00000138041.11chr255568193:55568363:55573618:55573777:55579678:55579781:55581566:55581698-0.23923.0521e-021.2157e-12-0.4226imageNNNAEosinophilsGSVA_HALLMARK_P53_PATHWAY
ENSG00000172840.5,PDP2
COADEAGIRENSG00000158623.10chr7130506247:130507372:130507684:1305078230.24502.3909e-025.7153e-160.4748imageNADAR;BUD13;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;DKC1;EIF4A3;EIF4G2;ELAVL1;ELAVL3;FAM120A;FBL;FMR1;FUS;FXR1;FXR2;GTF2F1;HNRNPA1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;IGF2BP1;IGF2BP2;IGF2BP3;KHDRBS1;KHDRBS2;KHDRBS3;LIN28;LIN28A;LIN28B;LSM11;METTL3;MOV10;MSI2;NONO;NOP56;NOP58;NUMA1;PCBP2;PRPF8;PTBP1;QKI;RANGAP1;RBFOX2;SAFB2;SLTM;SMNDC1;SND1;SRSF1;SRSF3;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TIAL1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;XRN2;YTHDC1;YTHDF1;ZNF184COPG2Dendritic_cells_activatedGSVA_HALLMARK_UV_RESPONSE_UP
chr16:66887640-66890279:+
COADEERMEXENSG00000214078.7chr2035627284:35627413:35630438:35630455:35630740:35630795:35630900:356310340.23813.1248e-024.9035e-150.4610imageNEIF4A3;ELAVL1;FUS;HNRNPK;IGF2BP2;RBFOX2;TARDBPNADendritic_cells_activatedGSVA_HALLMARK_SPERMATOGENESIS
chr16:66887640-66890279:+
COADEERA3ENSG00000011426.6chr736420223:36420314:36420611:36420744:36420596:364207440.21364.9133e-021.3817e-140.4598imageNEIF4A3;ELAVL1;FUS;HNRNPK;IGF2BP2;RBFOX2;TARDBPANLNDendritic_cells_activatedGSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALING
chr16:66887640-66890279:+
COADEERIRENSG00000158623.10chr7130506247:130507372:130507684:1305078230.24502.0854e-025.7153e-160.4748imageNEIF4A3;ELAVL1;FUS;HNRNPK;IGF2BP2;RBFOX2;TARDBPCOPG2Dendritic_cells_activatedGSVA_HALLMARK_UV_RESPONSE_UP
chr16:66887640-66890279:+
COADEERMEXENSG00000151247.8chr498884921:98885061:98887078:98887167:98891236:98891332:98901875:98901982-0.32941.9766e-041.0178e-11-0.4064imageNEIF4A3;ELAVL1;FUS;HNRNPK;IGF2BP2;RBFOX2;TARDBPEIF4EEosinophilsGSVA_HALLMARK_DNA_REPAIR
chr16:66887640-66890279:+
ESCAEERIRENSG00000156642.12chr1573563235:73563257:73563378:73563402-0.31461.6307e-026.8079e-07-0.4165imageNEIF4A3;ELAVL1;FUS;HNRNPK;IGF2BP2;RBFOX2;TARDBP;WTAPNPTNT_cells_regulatory_(Tregs)GSVA_HALLMARK_HYPOXIA

More results



Top

5. Enriched editing regions and immune infiltration for PDP2


all structure

check button Associations of enriched editing regions with immune infiltration.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the fraction of different immune cells according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeIDImmuneCellPRCorrelationPlot
chr16:66887640-66890279:+ACCEERT_cells_CD4_memory_activated2.1042e-03-0.3497image
ENSG00000172840.5,PDP2ACCEAGT_cells_CD4_memory_activated2.1042e-03-0.3497image
chr16:66887640-66890279:+BLCAEERMast_cells_resting2.6260e-020.1270image
ENSG00000172840.5,PDP2BLCAEAGMast_cells_resting2.6260e-020.1270image
chr16:66887640-66890279:+BRCAEERMast_cells_resting7.0678e-030.0875image
ENSG00000172840.5,PDP2BRCAEAGMast_cells_resting7.0678e-030.0875image
chr16:66887640-66890279:+CESCEERMonocytes1.9430e-02-0.1568image
ENSG00000172840.5,PDP2CESCEAGMonocytes1.9430e-02-0.1568image
chr16:66887640-66890279:+COADEEREosinophils4.4053e-040.2168image
ENSG00000172840.5,PDP2COADEAGEosinophils4.4053e-040.2168image
chr16:66887640-66890279:+DLBCEERB_cells_memory1.4805e-020.4557image
ENSG00000172840.5,PDP2DLBCEAGB_cells_memory1.4805e-020.4557image
chr16:66887640-66890279:+ESCAEERNK_cells_activated6.0420e-030.2175image
ENSG00000172840.5,PDP2ESCAEAGNK_cells_activated6.0420e-030.2175image
chr16:66887640-66890279:+GBMEERT_cells_CD4_memory_resting7.5477e-030.2138image
ENSG00000172840.5,PDP2GBMEAGT_cells_CD4_memory_resting7.5477e-030.2138image
chr16:66887640-66890279:+KICHEERT_cells_CD4_memory_activated3.6920e-020.2594image
ENSG00000172840.5,PDP2KICHEAGT_cells_CD4_memory_activated3.6920e-020.2594image
chr16:66887640-66890279:+KIRPEERDendritic_cells_resting2.8064e-020.1474image
ENSG00000172840.5,PDP2KIRPEAGDendritic_cells_resting2.8064e-020.1474image
ENSG00000172840.5,PDP2LAMLEAGMacrophages_M01.3854e-030.6648image
chr16:66887640-66890279:+LGGEERT_cells_CD4_naive2.5621e-02-0.0981image
ENSG00000172840.5,PDP2LGGEAGT_cells_CD4_naive2.5621e-02-0.0981image
chr16:66887640-66890279:+LUADEERT_cells_gamma_delta2.6245e-02-0.1104image
ENSG00000172840.5,PDP2LUADEAGT_cells_gamma_delta2.6245e-02-0.1104image
chr16:66887640-66890279:+LUSCEERB_cells_memory7.1787e-030.1298image
ENSG00000172840.5,PDP2LUSCEAGB_cells_memory7.1787e-030.1298image
chr16:66887640-66890279:+MESOEERT_cells_gamma_delta2.6339e-02-0.2821image
ENSG00000172840.5,PDP2MESOEAGT_cells_gamma_delta2.6339e-02-0.2821image
chr16:66887640-66890279:+OVEERT_cells_regulatory_(Tregs)4.0101e-02-0.1334image
ENSG00000172840.5,PDP2OVEAGT_cells_regulatory_(Tregs)4.0101e-02-0.1334image
chr16:66887640-66890279:+PCPGEERB_cells_memory8.5732e-030.2085image
ENSG00000172840.5,PDP2PCPGEAGB_cells_memory8.5732e-030.2085image
chr16:66887640-66890279:+SARCEERT_cells_CD82.0089e-02-0.2288image
ENSG00000172840.5,PDP2SARCEAGT_cells_CD82.0089e-02-0.2288image
chr16:66887640-66890279:+SKCMEERNK_cells_resting1.2916e-02-0.1220image
ENSG00000172840.5,PDP2SKCMEAGNK_cells_resting1.2916e-02-0.1220image
chr16:66887640-66890279:+STADEERMonocytes9.1376e-030.1437image
ENSG00000172840.5,PDP2STADEAGMonocytes9.1376e-030.1437image
chr16:66887640-66890279:+TGCTEERMast_cells_activated3.1230e-050.3704image
ENSG00000172840.5,PDP2TGCTEAGMast_cells_activated3.1230e-050.3704image
chr16:66887640-66890279:+THCAEERDendritic_cells_resting5.0611e-030.1254image
ENSG00000172840.5,PDP2THCAEAGDendritic_cells_resting5.0611e-030.1254image
chr16:66887640-66890279:+THYMEERDendritic_cells_activated8.9510e-090.5862image
ENSG00000172840.5,PDP2THYMEAGDendritic_cells_activated8.9510e-090.5862image
chr16:66887640-66890279:+UCECEERT_cells_gamma_delta4.6876e-030.2524image
ENSG00000172840.5,PDP2UCECEAGT_cells_gamma_delta4.6876e-030.2524image
chr16:66887640-66890279:+UVMEERT_cells_CD4_memory_activated8.4177e-040.4754image
ENSG00000172840.5,PDP2UVMEAGT_cells_CD4_memory_activated8.4177e-040.4754image


Top

6. Enriched editing regions and immune gene sets for PDP2


all structure

check button Correlation of enriched editing regions with epithelial-mesenchymal transition.
* First, the differences of enriched editing regions between Epi and Mes groups (defined by KS-test) were compared (P<0.05 and Informative number >=20).
* Second, the correlations between enriched editing regions and gene set score of HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the EERs/EAGs significantly edited between Epi and Mes group.
ID_eventscancerTypeE2M_PBoxplotCorPCorRCorrelationPlot


Top

check button Correlations of enriched editing regions with hypoxic.
* First, there are four hypoxia scores used in the database. The first three hypoxic scores were calculated on three gene sets of Buffa, Ragnum and Winter based on one previous study (PMID: 32024819). One last hypoxia score was defined on HALLMARK_HYPOXIA by GSVA method.
* Second, the correlations enriched editing regions with the four hypoxic scores were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the EERs/EAGs significantly correlated with all four hypoxia gene set scores. For more results, please go to download page.
ID_eventscancerTypeBuffa_P Buffa_R Ragnum_P Ragnum_R Winter_P Winter_R HALLMARK_P HALLMARK_R CorrelationPlot
chr16:66887640-66890279:+THCAEER1.7687e-040.16738.5646e-050.17514.2850e-020.09081.4549e-130.3231image
ENSG00000172840.5,PDP2THCAEAG1.7687e-040.16738.5646e-050.17514.2850e-020.09081.4549e-130.3231image


Top

check button Associations of enriched editing regions with hallmark gene sets from MSigDB.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerHallmarkTypeTypePRCorrelationPlot
ENSG00000172840.5,PDP2BLCAGSVA_HALLMARK_ESTROGEN_RESPONSE_EARLYEAG6.2630e-030.1560image
chr16:66887640-66890279:+BLCAGSVA_HALLMARK_ESTROGEN_RESPONSE_EARLYEER6.2630e-030.1560image
chr16:66887640-66890279:+BRCAGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER9.2591e-05-0.1267image
ENSG00000172840.5,PDP2BRCAGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG9.2591e-05-0.1267image
chr16:66887640-66890279:+COADGSVA_HALLMARK_GLYCOLYSISEER2.9540e-04-0.2231image
ENSG00000172840.5,PDP2COADGSVA_HALLMARK_GLYCOLYSISEAG2.9540e-04-0.2231image
chr16:66887640-66890279:+DLBCGSVA_HALLMARK_KRAS_SIGNALING_DNEER4.3665e-020.3840image
ENSG00000172840.5,PDP2DLBCGSVA_HALLMARK_KRAS_SIGNALING_DNEAG4.3665e-020.3840image
ENSG00000172840.5,PDP2ESCAGSVA_HALLMARK_HYPOXIAEAG8.9539e-050.3065image
chr16:66887640-66890279:+ESCAGSVA_HALLMARK_HYPOXIAEER8.9539e-050.3065image
chr16:66887640-66890279:+GBMGSVA_HALLMARK_XENOBIOTIC_METABOLISMEER5.6844e-050.3175image
ENSG00000172840.5,PDP2GBMGSVA_HALLMARK_XENOBIOTIC_METABOLISMEAG5.6844e-050.3175image
chr16:66887640-66890279:+HNSCGSVA_HALLMARK_KRAS_SIGNALING_DNEER3.5113e-020.1114image
ENSG00000172840.5,PDP2HNSCGSVA_HALLMARK_KRAS_SIGNALING_DNEAG3.5113e-020.1114image
chr16:66887640-66890279:+KICHGSVA_HALLMARK_APICAL_SURFACEEER1.2312e-04-0.4584image
ENSG00000172840.5,PDP2KICHGSVA_HALLMARK_APICAL_SURFACEEAG1.2312e-04-0.4584image
chr16:66887640-66890279:+KIRCGSVA_HALLMARK_COMPLEMENTEER7.2283e-030.1577image
ENSG00000172840.5,PDP2KIRCGSVA_HALLMARK_COMPLEMENTEAG8.6529e-030.1542image
ENSG00000172840.5,PDP2LAMLGSVA_HALLMARK_MITOTIC_SPINDLEEAG1.3697e-020.5414image
ENSG00000172840.5,PDP2LGGGSVA_HALLMARK_COAGULATIONEAG6.6111e-050.1744image
chr16:66887640-66890279:+LGGGSVA_HALLMARK_COAGULATIONEER6.6111e-050.1744image
ENSG00000172840.5,PDP2LIHCGSVA_HALLMARK_MITOTIC_SPINDLEEAG2.2261e-030.1847image
chr16:66887640-66890279:+LIHCGSVA_HALLMARK_MITOTIC_SPINDLEEER2.2261e-030.1847image
ENSG00000172840.5,PDP2LUSCGSVA_HALLMARK_KRAS_SIGNALING_UPEAG4.3356e-020.0977image
chr16:66887640-66890279:+LUSCGSVA_HALLMARK_KRAS_SIGNALING_UPEER4.3356e-020.0977image
chr16:66887640-66890279:+MESOGSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATIONEER1.9456e-02-0.2961image
ENSG00000172840.5,PDP2MESOGSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATIONEAG1.9456e-02-0.2961image
ENSG00000172840.5,PDP2PCPGGSVA_HALLMARK_TNFA_SIGNALING_VIA_NFKBEAG5.0100e-040.2737image
chr16:66887640-66890279:+PCPGGSVA_HALLMARK_TNFA_SIGNALING_VIA_NFKBEER5.0100e-040.2737image
chr16:66887640-66890279:+PRADGSVA_HALLMARK_PEROXISOMEEER6.6490e-03-0.1265image
ENSG00000172840.5,PDP2PRADGSVA_HALLMARK_PEROXISOMEEAG6.6490e-03-0.1265image
ENSG00000172840.5,PDP2READGSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALINGEAG6.0665e-040.3490image
chr16:66887640-66890279:+READGSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALINGEER6.0665e-040.3490image
ENSG00000172840.5,PDP2SARCGSVA_HALLMARK_UV_RESPONSE_DNEAG7.3447e-030.2627image
chr16:66887640-66890279:+SARCGSVA_HALLMARK_UV_RESPONSE_DNEER7.3447e-030.2627image
chr16:66887640-66890279:+SKCMGSVA_HALLMARK_APICAL_JUNCTIONEER2.9837e-030.1454image
ENSG00000172840.5,PDP2SKCMGSVA_HALLMARK_APICAL_JUNCTIONEAG2.9837e-030.1454image
chr16:66887640-66890279:+STADGSVA_HALLMARK_TNFA_SIGNALING_VIA_NFKBEER1.9953e-030.1701image
ENSG00000172840.5,PDP2STADGSVA_HALLMARK_TNFA_SIGNALING_VIA_NFKBEAG1.9953e-030.1701image
ENSG00000172840.5,PDP2TGCTGSVA_HALLMARK_HYPOXIAEAG1.1860e-020.2290image
chr16:66887640-66890279:+TGCTGSVA_HALLMARK_HYPOXIAEER1.1860e-020.2290image
chr16:66887640-66890279:+THCAGSVA_HALLMARK_HYPOXIAEER1.4549e-130.3231image
ENSG00000172840.5,PDP2THCAGSVA_HALLMARK_HYPOXIAEAG1.4549e-130.3231image
ENSG00000172840.5,PDP2UCECGSVA_HALLMARK_IL6_JAK_STAT3_SIGNALINGEAG3.2297e-02-0.1924image
chr16:66887640-66890279:+UCECGSVA_HALLMARK_IL6_JAK_STAT3_SIGNALINGEER3.2297e-02-0.1924image
ENSG00000172840.5,PDP2UCSGSVA_HALLMARK_HEDGEHOG_SIGNALINGEAG1.8843e-02-0.4007image
chr16:66887640-66890279:+UCSGSVA_HALLMARK_HEDGEHOG_SIGNALINGEER1.8843e-02-0.4007image
ENSG00000172840.5,PDP2UVMGSVA_HALLMARK_MYC_TARGETS_V1EAG4.0700e-030.4156image
chr16:66887640-66890279:+UVMGSVA_HALLMARK_MYC_TARGETS_V1EER4.0700e-030.4156image


Top

7. Enriched editing regions and drugs for PDP2


all structure

check button Correlations between enriched editing regions and drug sensitivity.
* First, the drug sensitivity (IS50) was estimated on 84 drugs by pRRophetic package.
* Second, the correlations between editing enriched regions and drug sensitivity were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the IS50 scores of 84 drugs according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerDrugTypePRCorrelationPlot
chr16:66887640-66890279:+ACCAZD6244EER1.2479e-030.3658image
ENSG00000172840.5,PDP2ACCAZD6244EAG1.2479e-030.3658image
chr16:66887640-66890279:+BLCAIPA.3EER2.3305e-020.1297image
ENSG00000172840.5,PDP2BLCAIPA.3EAG2.3305e-020.1297image
ENSG00000172840.5,PDP2BRCAAKT.inhibitor.VIIIEAG1.1739e-03-0.1054image
chr16:66887640-66890279:+BRCAAKT.inhibitor.VIIIEER1.1739e-03-0.1054image
chr16:66887640-66890279:+CESCGemcitabineEER5.7142e-030.1849image
ENSG00000172840.5,PDP2CESCGemcitabineEAG5.7142e-030.1849image
chr16:66887640-66890279:+COADGW843682XEER6.6555e-050.2452image
ENSG00000172840.5,PDP2COADGW843682XEAG6.6555e-050.2452image
ENSG00000172840.5,PDP2DLBCA.443654EAG1.0157e-020.4776image
chr16:66887640-66890279:+DLBCA.443654EER1.0157e-020.4776image
chr16:66887640-66890279:+ESCABexaroteneEER3.1593e-05-0.3246image
ENSG00000172840.5,PDP2ESCABexaroteneEAG3.1593e-05-0.3246image
ENSG00000172840.5,PDP2GBMBI.D1870EAG3.3775e-040.2842image
chr16:66887640-66890279:+GBMBI.D1870EER3.3775e-040.2842image
chr16:66887640-66890279:+HNSCElesclomolEER2.9768e-020.1149image
ENSG00000172840.5,PDP2HNSCElesclomolEAG2.9768e-020.1149image
chr16:66887640-66890279:+KICHABT.263EER4.1769e-040.4250image
ENSG00000172840.5,PDP2KICHABT.263EAG4.1769e-040.4250image
ENSG00000172840.5,PDP2KIRCAZD.2281EAG8.8677e-03-0.1540image
chr16:66887640-66890279:+KIRCAZD.2281EER7.5125e-03-0.1572image
ENSG00000172840.5,PDP2KIRPGDC.0449EAG3.5684e-04-0.2375image
chr16:66887640-66890279:+KIRPGDC.0449EER3.5684e-04-0.2375image
ENSG00000172840.5,PDP2LAMLATRAEAG1.0380e-04-0.7592image
chr16:66887640-66890279:+LGGBryostatin.1EER1.5679e-08-0.2452image
ENSG00000172840.5,PDP2LGGBryostatin.1EAG1.5679e-08-0.2452image
ENSG00000172840.5,PDP2LIHCATRAEAG8.3877e-04-0.2043image
chr16:66887640-66890279:+LIHCATRAEER8.3877e-04-0.2043image
ENSG00000172840.5,PDP2LUSCA.443654EAG1.7200e-020.1151image
chr16:66887640-66890279:+LUSCA.443654EER1.7200e-020.1151image
chr16:66887640-66890279:+MESOErlotinibEER1.9333e-020.2964image
ENSG00000172840.5,PDP2MESOErlotinibEAG1.9333e-020.2964image
ENSG00000172840.5,PDP2OVATRAEAG5.3887e-030.1802image
chr16:66887640-66890279:+OVATRAEER5.3887e-030.1802image
ENSG00000172840.5,PDP2PCPGBI.D1870EAG5.4474e-030.2201image
chr16:66887640-66890279:+PCPGBI.D1870EER5.4474e-030.2201image
ENSG00000172840.5,PDP2PRADGefitinibEAG1.5511e-05-0.2002image
chr16:66887640-66890279:+PRADGefitinibEER1.5511e-05-0.2002image
ENSG00000172840.5,PDP2READEmbelinEAG2.1878e-02-0.2375image
chr16:66887640-66890279:+READEmbelinEER2.1878e-02-0.2375image
ENSG00000172840.5,PDP2SARCBicalutamideEAG7.6463e-03-0.2614image
chr16:66887640-66890279:+SARCBicalutamideEER7.6463e-03-0.2614image
chr16:66887640-66890279:+SKCMAZD.0530EER2.1154e-03-0.1505image
ENSG00000172840.5,PDP2SKCMAZD.0530EAG2.1154e-03-0.1505image
chr16:66887640-66890279:+STADLFM.A13EER1.3236e-04-0.2095image
ENSG00000172840.5,PDP2STADLFM.A13EAG1.3236e-04-0.2095image
ENSG00000172840.5,PDP2TGCTAUY922EAG4.2696e-03-0.2591image
chr16:66887640-66890279:+TGCTAUY922EER4.2696e-03-0.2591image
chr16:66887640-66890279:+THCAIPA.3EER1.2013e-080.2519image
ENSG00000172840.5,PDP2THCAIPA.3EAG1.2013e-080.2519image
ENSG00000172840.5,PDP2THYMBIBW2992EAG2.6882e-02-0.2460image
chr16:66887640-66890279:+THYMBIBW2992EER2.6882e-02-0.2460image
chr16:66887640-66890279:+UCECDMOGEER1.8463e-020.2113image
ENSG00000172840.5,PDP2UCECDMOGEAG1.8463e-020.2113image
chr16:66887640-66890279:+UCSCisplatinEER3.6892e-020.3593image
ENSG00000172840.5,PDP2UCSCisplatinEAG3.6892e-020.3593image
ENSG00000172840.5,PDP2UVMBMS.708163EAG2.4342e-02-0.3317image
chr16:66887640-66890279:+UVMBMS.708163EER2.4342e-02-0.3317image


Top

check button EAGs targeted by drugs from DrugBank database.
* EAG: EER-associated genes.
EERENSTUniprotIDDrugBankIDDrugDrugType